Qumis | $2,200,000 | (Jan 22, 2025)
Zynap | $5,937,902 | (Jan 22, 2025)
Belfry | $12,000,000 | (Jan 22, 2025)
Certified by Founder
Lodge
Odyssey Therapeutics
start up
United States
- Boston, Massachusetts
- 06/12/2023
- Series C
- $101,000,000
At Odyssey, we are creating next generation precision medicines for patients with cancer and inflammatory diseases with class-leading speed, efficiency and rigor through our highly integrated drug hunting engine.
- Industry Biotechnology Research
- Website https://www.odysseytx.com/
- LinkedIn https://www.linkedin.com/company/odyssey-tx/about/
Gravity | $13,000,000 | (Jan 22, 2025)
LeapXpert | $20,000,000 | (Jan 22, 2025)
BPR Hub | $2,600,000 | (Jan 22, 2025)
NovoLINC | Undisclosed Amount | (Jan 22, 2025)
IntusCare | $11,500,000 | (Jan 21, 2025)
ecoplanet | $16,571,680 | (Jan 21, 2025)
Sereact | $25,894,660 | (Jan 21, 2025)
Fundment | $55,157,175 | (Jan 21, 2025)
Men In Blazers Media Network | $150,000,000 | (Jan 21, 2025)